NYSE:MRKPharmaceuticals
Merck Broadens Growth Drivers With Women’s Health And Infant RSV Moves
Merck (NYSE:MRK) has entered a collaboration with Calla Lily Clinical Care to develop a novel intravaginal drug delivery platform using the Callavid device.
Health Canada has approved Merck’s ENFLONSIA (clesrovimab), an RSV prevention therapy for infants, expanding the company’s reach in pediatric respiratory care.
For investors watching Merck’s mix of businesses, these developments sit outside the company’s oncology focus and add more weight to its broader pharmaceutical portfolio. The...